Startup profile · funding coverage
Alpha-9 Oncology
Clinical-stage radiopharmaceutical company developing targeted cancer therapies.
Stage
growth
Status
private
Coverage
full
Why Alpha-9 Oncology is interesting
Systematic radiopharma design engine across validated and novel oncology targets — oversubscribed Series C at scale.
Key facts
- Series C (2024): $175M led by Lightspeed and Ascenta with a16z Bio + Health, General Catalyst (company press)
- Clinical-stage radiopharmaceutical platform targeting multiple oncology indications via systematic ligand design
- Co-investors not in VCT directory: Ascenta Capital
Investors in our directory
Funds linked from Alpha-9 Oncology's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Alpha-9 Oncology's financing or category context.
FAQs about Alpha-9 Oncology
Funding context and why this company shows up in venture coverage.
Alpha-9 is a clinical-stage radiopharma company designing targeted cancer therapies using a systematic platform across validated and novel oncology targets.
a16z Bio + Health participated in the $175M Series C (2024). Directory-linked: /fund/andreessen-horowitz, /fund/general-catalyst, /fund/lightspeed-venture-partners-nyc.
Growth-stage clinical biotech after an oversubscribed $175M Series C (2024) led by Lightspeed and Ascenta.
Radiopharmaceuticals are having a clinical renaissance (e.g., Pluvicto). Alpha-9's platform approach targets multiple indications beyond single-asset bets.
No — remains private as of July 2026.
Last updated: 2026-07-24